Synergistic Anticancer Efficacy of MEK Inhibition and Dual PI3K/mTOR Inhibition in Castration-Resistant Prostate Cancer

被引:35
作者
Park, Hongzoo [1 ]
Kim, Yunlim [2 ,3 ,4 ]
Sul, Jee-Won [3 ,4 ]
Jeong, In Gab [2 ]
Yi, Hye-Jin [3 ,4 ]
Ahn, Jae Beom [4 ]
Kang, Jong Soon [5 ]
Yun, Jieun [5 ]
Hwang, Jung Jin [3 ,4 ]
Kim, Choung-Soo [2 ,3 ,4 ]
机构
[1] Kangwon Natl Univ, Kangwon Natl Univ Hosp, Sch Med, Dept Urol, Chunchon, Gangwon Do, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul 138736, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Inst Innovat Canc Res, Seoul 138736, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Inst Life Sci, Seoul 138736, South Korea
[5] Korea Res Inst Biosci & Biotechnol, Bioevaluat Ctr, Ochang, Cheongwon, South Korea
关键词
castration-resistant prostate cancer; MEK inhibitor; PI3K inhibitor; prostate cancer; targeted therapy; TARGETED THERAPY; MOUSE MODEL; FEEDBACK; PATHWAY; COMBINATION; ACTIVATION; CARCINOMA; APOPTOSIS; MEMBRANE; GROWTH;
D O I
10.1002/pros.23057
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. PTEN deletion, mutation or reduced expression occurs in 63% of metastatic prostate tumors, resulting in the activation of PI3K and its downstream targets, AKT and mTOR. Inhibition of the PI3K pathway results in upregulation of the MAPK pathway. Therefore, co-administration of inhibitors of both pathways, GSK2126458 as a dual PI3K/mTOR inhibitor, and AZD6244 as a MEK inhibitor, is able to overcome resistance and increase anti-tumor efficacy. METHODS. PC3, DU145, LNCaP, and CRPC patient-derived cells were used to assess apoptosis upon exposure to the drug combination. The human DU145 and PC3 tumor xenograft mouse model was employed to evaluate in vivo efficacy. CellTiter Glo (R) luminescent assay, annexin V-FITC apoptosis detection, cell cycle analysis, Western blotting and immunohistochemistry were conducted. Statistical evaluation of the results was performed by one-way ANOVA. RESULTS. The combination of GSK2126458 and AZD6244 inhibited the growth of DU145 and PC3 prostate cancer cells in vitro and in vivo. GSK2126458 decreased phospho-AKT while increasing phospho-ERK and AZD6244 decreased phospho-ERK efficiently while increasing phospho-AKT. The combination of GSK2126458 and AZD6244 decreased both phospho-AKT and phospho-ERK effectively in vitro and in vivo. The combination treatment synergistically induced annexin V-positive cells, sub-G1 cells, and cleavage of caspase-9, caspase-3 and poly-ADP ribose polymerase (PARP) in DU145 cells in vitro. Moreover, the combination decreased the level of Ki-67, and increased TUNEL-positive cells and cleaved caspase-3 in DU145 xenograft tumors implanted in mice. In addition, this combination treatment inhibited both the PI3K and MEK pathway primary in cultures from CRPC patients harboring PTEN loss, leading to synergistic anti-tumor effect. CONCLUSIONS. The combination of GSK2126458 and AZD6244 blocks both the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways simultaneously and is an effective strategy for the treatment of CRPCs. (C) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:1747 / 1759
页数:13
相关论文
共 29 条
[1]   Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].
Adjei, Alex A. ;
Cohen, Roger B. ;
Franklin, Wilbur ;
Morris, Clive ;
Wilson, David ;
Molina, Julian R. ;
Hanson, Lorelei J. ;
Gore, Lia ;
Chow, Laura ;
Leong, Stephen ;
Maloney, Lara ;
Gordon, Gilad ;
Simmons, Heidi ;
Marlow, Allison ;
Litwiler, Kevin ;
Brown, Suzy ;
Poch, Gregory ;
Kane, Katie ;
Haney, Jerry ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146
[2]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[3]  
Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]
[4]   Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer [J].
Carver, Brett S. ;
Chapinski, Caren ;
Wongvipat, John ;
Hieronymus, Haley ;
Chen, Yu ;
Chandarlapaty, Sarat ;
Arora, Vivek K. ;
Le, Carl ;
Koutcher, Jason ;
Scher, Howard ;
Scardino, Peter T. ;
Rosen, Neal ;
Sawyers, Charles L. .
CANCER CELL, 2011, 19 (05) :575-586
[5]   Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer [J].
Chandarlapaty, Sarat .
CANCER DISCOVERY, 2012, 2 (04) :311-319
[6]   Castration-Resistant Prostate Cancer: AUA Guideline [J].
Cookson, Michael S. ;
Roth, Bruce J. ;
Dahm, Philipp ;
Engstrom, Christine ;
Freedland, Stephen J. ;
Hussain, Maha ;
Lin, Daniel W. ;
Lowrance, William T. ;
Murad, Mohammad Hassan ;
Oh, William K. ;
Penson, David F. ;
Kibel, Adam S. .
JOURNAL OF UROLOGY, 2013, 190 (02) :429-438
[7]  
Dhingra R, 2013, MINI-REV MED CHEM, V13, P1475
[8]   Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer [J].
Gao, Hui ;
Ouyang, Xuesong ;
Banach-Petrosky, Whitney A. ;
Gerald, William L. ;
Shen, Michael M. ;
Abate-Shen, Cory .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (39) :14477-14482
[9]   Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer [J].
Gioeli, Daniel ;
Wunderlich, Winfried ;
Sebolt-Leopold, Judith ;
Bekiranov, Stefan ;
Wulfkuhle, Julia D. ;
Petricoin, Emanuel F., III ;
Conaway, Mark ;
Weber, Michael J. .
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (09) :1581-1590
[10]   EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer [J].
Heidenreich, Axel ;
Bastian, Patrick J. ;
Bellmunt, Joaquim ;
Bolla, Michel ;
Joniau, Steven ;
van der Kwast, Theodor ;
Mason, Malcolm ;
Matveev, Vsevolod ;
Wiegel, Thomas ;
Zattoni, Filiberto ;
Mottet, Nicolas .
EUROPEAN UROLOGY, 2014, 65 (02) :467-479